Verastem promotes COO Robert Forrester to president Verastem promoted Robert Forrester to President in addition to COO. Verastem is planning multiple clinical trials for 2013 across its programs targeting FAK and PI3K/mTOR. The current clinical plans include a midyear initiation of a potentially pivotal trial in mesothelioma for lead FAK inhibitor, VS-6063.
News For VSTM From The Last 14 Days
Check below for free stories on VSTM the last two weeks.
UBS to host a conference Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link